Company intelligence / Profile preview

Ocontech

Malvern, Pennsylvania, United Statesocontech.com ↗

Ownership: Private
Employees: ~51
Development stage: Other

Overview

Ocugen's modifier gene therapy platform has shown consistent stabilization or improvement in treated eyes across ongoing clinical programs for inherited retinal diseases. The OCU410ST program for Stargardt disease is entering a pivotal Phase 2/3 trial after FDA alignment and has received Rare Pediatric Disease Designation and Orphan Drug Designation. Other candidates are advancing through early-to-mid stage trials with encouraging safety/tolerability profiles.

Therapeutic areas: OphthalmologyInfectious Diseases
Modalities: Gene therapyCell therapyBiologicVaccine
Industry: Biotech

Partnerships

Bharat Biotech International Limited – exclusive North American rights for COVAXIN™ COVID‑19 vaccine.

Beyond the preview

Go deeper on Ocontech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ocontech.

Explore the full profile